Roche Says Breast-Cancer Drug Shows Potential to Become Standard-Of-Care
GE Vernova Inc.(US:GEV) WSJ·2025-12-10 22:20Giredestrant lowered the risk of disease recurrence or death by 30%, compared with standard-of-care endocrine therapy, according to the company. ...